Loading...
NASDAQ: IMNN
Imunon, Inc.
Healthcare · Biotechnology
Market Cap
$7.44M
52w High
$41.22
52w Low
$2.86
P/E
-0.61
Volume
22.98K
Outstanding Shares
2.52M
Company profile
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.
CEOStacy R. Lindborg
SectorHealthcare
IndustryBiotechnology
Employees25
IPO dateMar 1, 1999
Valuation
Forward P/E—
EV/EBITDA-0.44
Enterprise value$7.84M
Stock splits
Jul 25, 20251:15
Mar 1, 20221:15
May 30, 20171:14
Oct 29, 2013111:500
Feb 28, 20061:15
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-438.71%▼200.96%vs FY2023
Analyst consensus
RatingBuy
Target price—
3
Buy
1
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 11, 2026
View
EPS
Actual vs estimate by quarter
Q1FY25
ActualEst.
-$3.65
-$4.56
Q2FY25
ActualEst.
-$1.87
-$3.09
Q3FY25
ActualEst.
-$1.16
-$1.73
Q4FY25
Next Est.
—
Revenue
Actual vs estimate by quarter
Q1FY25
ActualEst.
—
—
Q2FY25
ActualEst.
—
—
Q3FY25
ActualEst.
—
—
Q4FY25
Next Est.
—